May 13, 2025 12:44 PM EDTUpdated 02:22 PM
Pharma
Law

HHS fo­cus­es on 'trans­paren­cy' in third-round IRA ne­go­ti­a­tion guid­ance

Alexis Kramer

Deputy Editor

The Trump ad­min­is­tra­tion laid out for the first time how Part B drugs could be se­lect­ed for Medicare drug price ne­go­ti­a­tions un­der guid­ance that seeks …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

CRISPR patent spat re­vived by fed­er­al ap­peals court rul­ing

TIG­IT grave­yard ex­pands as GSK drops late-stage as­set with iTeos

Unit­ed­Health Group CEO An­drew Wit­ty steps down

Up­dat­ed: To spin off or not to spin off? Gala­pa­gos backpedals on sep­a­ra­tion plans, CEO Paul Stof­fels ex­its ear­ly

Bay­er starts 2025 by cut­ting 2,000 jobs as it homes in on year-end re­haul tar­get

Some gener­ics, biosim­i­lar drug­mak­ers say they can with­stand tar­iff im­pact

A service from the Financial Times